In addition to immunological checkpoints inhibitors to restore the T cell anti-cancer immunity [93] and the above mentioned CART cells for cancer immunotherapy, two strategies have been designed recently to reactivate innate immunity against tumors by: (1) activating macrophages or polymorphonuclear neutrophils with anti-CD47 antibody, and (2) use of anti-tumor antibody to induce antibody-dependent cell-mediated cytotoxicity (ADCC) by innate immune cells. This evidence concerns the gene CD47 and neoplasm.